In the very first issue of this Journal published in 1992, we declared that human molecular genetics had ‘clearly come of age’ and that there was a real need for a new journal because of the vast amount of information accumulating from genome studies. It is very satisfying to look back on how the Journal was then and how it has adapted to the ever changing and exciting landscape of human genetics. In 1992, we had RFLP reports as well as mutation reports. These were an essential part of the positional cloning of disease genes. We introduced Annual Review Issues in 1994 to provide the human genetics community with concise, up-to-date accounts of progress in the field. These issues have been so successful that we now also publish an annual Special Review Issue which focuses on a particular area with guest editors. The first Review Issue included contributions on the value of yeast and mouse models in disease gene analysis as well as the role of methylation in cancer. The latter fits well with the recent Special Review Issue on Epigenetics indicating how much this area has advanced. In 1992, Human Molecular Genetics filled a niche and it has grown in stature over the last 14 years. We now publish bi-monthly and have two review issues per year.
Over the years, Human Molecular Genetics has shifted its focus from the cloning of disease genes to the application of genetics to the understanding of the genetic and biochemical pathways important for the development and function of mammalian genes. The Journal continues to grow. Our remit remains to promote the original science that contributes to a greater understanding of human disease, therapies and the function of the human genome.
When Hunt Willard and I began discussions about starting a new journal back in 1991, little did we realize that we would still be at it some 14 years later. Much has changed during that time not only in the field, but also in the journal business, and in our careers. The success of the Journal and the pleasure of being editor have in large part been due to the working partnership with Hunt. It has always been rewarding to note how much synergy in purpose and ideals have existed between the two offices (even in the acceptance rates!). Hunt is now stepping down to concentrate more on his other responsibilities. I would like to take this opportunity to thank him for his unstinting support and hard work for Human Molecular Genetics (at all hours of the day and night). We wish him well in the future. Fortunately, he will not be lost completely as he will continue to provide good counsel through his role as ‘Consulting Editor’.
Looking to the future, it is with great pleasure that Human Molecular Genetics announces the appointment of Anthony Wynshaw-Boris as a new Executive Editor. Tony is an MD, PhD with a keen interest in the use of model systems as an entry point to investigate pathways critical for normal brain development and function. His group have played a major role in identifying the genes responsible for human disease of the central nervous system and are now focussed on the understanding of these diseases and the development of novel therapeutic approaches. Tony is therefore well suited to take up this position. He has been working with us over the last few months, gradually taking charge of the North American Office. I am looking forward to working with him in the next phase of the Journal's evolution.
| ||||||||||||||||||||||||||||||||||||||||||||||||